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Abstract 
Review on MIR122, with data on DNA/RNA and 
where the gene is implicated. 
Identity 
Other names: MIR122A, MIRN122, MIRN122A, 
hsa-mir-122, miRNA122, miRNA122A 
HGNC (Hugo): MIR122 
Location: 18q21.31 
Local order: miRNA-122 is located on the positive 
strand of chromosome 18 at 18q21.31. It is between 
base pairs 56118306-56118390 and is composed of 
85 nucleotides encoding a single exon. NCBI gene 
ID is 406906. 
The genes located on the chromosome near 
miRNA-122, listed in order from centromere to 
telomere on Mapviewer Master Map. 
Genes on sequence are: 
- LOC100132992 NMGN1P30 (18q21.31, negative 
strand): high mobility group nucleosome binding 
domain 1 pseudogene 30; 
- NEDD4L (18q21, positive strand): neuronal 
precursor cell expressed developmentally down-
regulated 4-like, E3 ubiquitin protein ligase; 
- MIR122 (18q21.31, positive strand): 
microRNA-122; 
- MIR3591 (negative strand): microRNA-3591; 
- ALPK2 (18q21.31, negative strand): alpha-kinase  
 
 
2; 
- RPL9P31 (18q21, positive strand): ribosomal 
protein L9 pseudogene 31. 
Note 
miR-122 clusters with miR-3591, which is located 
on the negative strand of chromosome 18 between 
base pairs 56118312-56118384. miR-3591 is part 
of the miR-122 gene family and is processed into 
two different mature forms (miRBase). 
DNA/RNA 
Note 
miR-122 sequence: 
Pre-miRNA sequence: 
5'-
CCUUAGCAGAGCUGUGGAGUGUGACAAUG
GUGUUUGUGUCUAAACUAUCAAACGCCAU 
UAUCACACUAAAUAGCUACUGCUAGGC-3' 
Mature miR-122 sequences associated with this 
pre-miRNA sequence: 
MIR 122-5P 15-
UGGAGUGUGACAAUGGUGUUUG-36 
MIR 122-3P 51-
AACGCCAUUAUCACACUAAAUA-72 
Primary isoforms of miR-122-5P: 
UGGAGUGAGACAAUGGUGUUU 
UGGAGUGAGACAAUGGUGUUUG 
(Sequences from miRBase.) 
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Figure1. Genomic context for chromosome 18 surrounding MIR122 (figure adapted from NCBI Gene). 
 
 
 
Figure 2. Stem-loop structure of pre-miR-122. The pink highlighted regions indicate the mature miR-122 duplex; the top pink 
sequence is the hsa-miR-122-5P sequence and the bottom pink sequence is the hsa-miR-122-3P sequence (diagram adapted 
from miRBase). 
 
 
Description 
The coding sequence for microRNA-122 (miR-122) 
comprises a single locus on the human chromosome 
18 (Jopling, 2012). After transcription and 
processing, miR-122 is loaded onto an RNA-
Induced Silencing Complex (RISC), comprised of 
Argonaute 2 (Ago-2), GW182, and other proteins 
(Wilson and Huys, 2013), where the miRNA 
duplex is unwound and one strand, the "guide 
strand" is retained and the other strand, the 
"passenger strand", is discarded. The miRNA guide 
strand directs the RISC to target mRNAs based on 
imperfect sequence complementarity. Important 
base-pairing occurs between nucleotides 2 - 8 of the 
miRNA (the seed sequence) and the 3' un-translated 
region (UTR) of the target mRNA (Du and Zamore, 
2005). RISC binding directs the repressed mRNA 
to a processing (P)-body, where the mRNA is 
sequestered and/or degraded (Wilson and Huys, 
2013). miR-122 antagonism shows that miR-122 
regulates, directly or indirectly, at least 199 liver 
mRNAs (Elmén et al., 2008). 
Transcription 
miRNA messenger RNAs are transcribed by RNA 
polymerase II, which generates a primary miRNA 
transcript (pri-miRNA) (Saj and Lai, 2011). Pri-
miRNAs can encode a single miRNA, or multiple 
miRNAs expressed as a cluster (Arora et al., 2013). 
Unspliced pri-miR-122 is 7506 bp in length and 
only encodes miR-122; following splicing, the pri-
miR-122 transcript is 4543 bp (Li et al., 2011). The 
spliced pri-miRNA contains a miR-122 stem-loop 
that is cleaved by a complex of Drosha, a nuclear 
RNase III enzyme, and DGCR8, a double-stranded 
RNA-binding protein to form the pre-miR-122 
hairpin (Saj and Lai, 2011; Arora et al., 2013). The 
pre-miRNA is exported from the nucleus and 
cleaved once more in the cytoplasm by Dicer, an 
RNase III enzyme, resulting in the double-stranded 
miRNA duplex (figure 2) (Saj and Lai, 2011). 
Studies have shown that expression of human miR-
122 is highest in liver tissues, but is also detected in 
the nervous and respiratory systems (Landgraf et 
al., 2007).  
The same study showed that miR-122 is 
differentially expressed in cells of hematopoietic 
lineage (Landgraf et al., 2007).  
Regulation of miR-122 expression is not fully 
characterized, but involves liver enriched 
transcription factors (LETFs). LETF HNF4α binds 
to the miR-122 promoter region and positively 
regulates miR-122 expression in human hepatoma 
Huh-7 cells and in mouse liver (Li et al., 2011).  
Increased miR-122 results in activation of a number 
of transcriptional targets associated with , one of 
the key central regulators involved in miR-122 gene 
activation (Coulouarn et al., 2009).  
Other liver factors proposed to control miR-122 
expression include HNF1A, HNF3A and HNF3B: a 
decrease in any of these factors results in reduced 
miR-122 expression; the same trend also occurs 
with HNF4G and HNF6 but to a lesser extent 
(Coulouarn et al., 2009). HNF6 is also part of a 
positive feedback loop that includes miR-122 and 
stimulates expression of various hepatocyte-specific 
genes and other LETFs required for hepatocyte 
differentiation (Laudadio et al., 2012).  
In addition, peroxisome proliferator activated 
receptor-gamma (PPARγ) and retinoid X receptor 
alpha (RXRα), can transcriptionally activate miR-
122 (Song et al., 2013), but interestingly PPARγ 
inhibits miR-122 expression when bound by the 
hepatitis B virus X protein (Song et al., 2013).  
The variety of transcription factors that have direct 
or indirect roles on miR-122 expression allude to its 
multitude of functions. 
Protein 
Note 
There is no protein associated with MIR 122. 
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Figure 3. A. Location of SNPs near the mature miR-122 coding sequence. The highlighted region is the miR-122 sequence and 
the location of rs41292412 is indicated by the red line (diagram adapted from miRNASNP). B. Location of rs4129412 (green: C 
to T mutation in the chromosomal coding) in the miR-122 duplex (modified from miRBase). 
 
Mutations 
Note 
There are 72 single nucleotide polymorphisms 
(SNPs) associated with the miR-122 transcript, but 
only one is found within the mature miR-122 
sequence. The SNP ID is rs41292412, a C to T 
mutation located in the chromosome at 56118358, 
within the hsa-miR-122-3P mature sequence. Other 
SNPs can be found on NCBI database; GeneCards; 
and microRNA-related single nucleotide 
polymorphisms (miRNASNP). 
Germinal 
No. 
Somatic 
Yes. 
Implicated in 
Hepatocellular carcinoma (HCC) 
Note 
miR-122 has been identified as a tumour-suppressor 
microRNA; loss of miR-122 expression has been 
observed in cases of hepatocellular carcinoma, and 
its function in suppressing tumour-like functions 
have been verified in animal and cell culture 
models (Bai et al., 2009; Coulouarn et al., 2009; 
Hsu et al., 2012; Kutay et al., 2006). 
Prognosis 
In miR-122 knockout mice, addition of exogenous 
miR-122 strongly suppressed tumourigenesis (Hsu 
et al., 2012). Restoration of miR-122 expression to 
hepatocellular carcinoma cells increased their 
sensitivity to chemotherapeutics adriamycin and 
vincristine; this was also marked by miR-122-
mediated reduction of MDR-1, GST-π, MRP, Bcl-
w, and Cyclin B1, aiding in induction of cell cycle 
arrest (Xu et al., 2011). Addition of miR-122 to 
HCC cells also rendered them more susceptible to 
doxorubicin treatment (Fornari et al., 2009). miR-
122 is believed to aid many chemotherapeutic 
agents in hepatocellular carcinoma by 
downregulating the unfolded protein response, 
permitting therapeutic apoptosis that would 
otherwise be suppressed in cancer cells (Yang et al., 
2011). The level of miR-122 in human serum is 
also being explored as a potential biomarker to 
detect hepatocellular carcinoma development and 
progression (Ding et al., 2012). 
Oncogenesis 
miR-122 is hypothesized to regulate terminal 
hepatocyte differentiation, and loss of its expression 
(with subsequent upregulation of stem cell-
associated proteins such as Pkm2) is a potential step 
towards hepatocellular carcinoma development 
(Jung et al., 2011). Loss of expression in HCC 
tumour samples and cell lines resulted in 
acquisition of migration and invasive properties 
(Coulouarn et al., 2009; Tsai et al., 2009). 
Exogenous miR-122 was found to limit cell growth 
and promote apoptosis in hepatocellular carcinoma 
cell lines by suppressing Wnt1, which disrupts the 
canonical Wnt/β-catenin proliferation pathway (Xu 
et al., 2012). A subset of individuals with HCC 
have also been identified to bear a polymorphism 
(rs3783553) in the 3' UTR of IL-1α which is 
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hypothesized to disrupt a miR-122 binding site. IL-
1α is implicated in carcinogenesis and tumour 
growth, as well as immune responses to tumours, 
and miR-122 regulation of IL-1α under normal 
circumstances may be an aspect of its tumour 
suppressor function (Gao et al., 2009). miR-122 
knockout mice are observed to develop 
hepatosteatosis, hepatitis, and hepatic tumours (Hsu 
et al., 2012). Increases in oncogenic pathways, 
along with inflammation and pro-inflammatory 
cytokine production such as IL-6 and TNF were 
also observed in the livers of these mice (Hsu et al., 
2012). 
Cutaneous T-cell lymphoma (CTCL) 
Oncogenesis 
miR-122 is not normally expressed to high levels in 
T-cells, but has been identified in CTCL to be 
induced by p53 in response to chemotherapy, and 
reduce apoptosis of lymphomatous cells by 
stimulating Akt kinase with an unknown 
mechanism (Manfè et al., 2012). This is contrary to 
its normal pro-apoptotic (tumour suppressor) 
function in other cancers such as hepatocellular 
carcinoma. 
Gastrointestinal cancers 
Note 
Although miR-122 is not expressed in high levels 
within the intestinal tract, it was found to be 
downregulated in both primary tumours and 
gastrointestinal cancer cell lines, in comparison to 
normal tissues (Wang et al., 2009). In a rat model 
of colorectal cancer, this downregulation in healthy 
tissues was predictive of carcinogenesis elsewhere 
in the colon, and could be monitored from fecal 
colonocytes in the stool (Kunte et al., 2012). 
Oncogenesis 
It is implicated in partnering with the tumour 
suppressor gene APC (adenomatous polyposis coli), 
which degrades β-catenin and prevents proliferative 
signaling, as sequestration of miR-122 reversed 
APC-mediated growth inhibition, while addition of 
exogenous miR-122 restored growth inhibition in 
uncontrolled cells (Wang et al., 2009). 
Pancreatic adenocarcinoma 
Note 
miR-122 was found to be underexpressed in ductal 
pancreatic adenocarcinoma samples 
(Papaconstantinou et al., 2013). 
Breast cancer 
Note 
miR-122 was identified in serum deep sequencing 
of stage II-III breast cancer patients, with increased 
levels of miR-122 correlating with and later 
predicting non-responsiveness to neoadjuvant 
chemotherapy and metastatic outcomes (Wu et al., 
2012). 
Tumour suppressor activity 
Note 
miR-122 has been implicated as a tumour 
suppressor in several different conditions, 
particularly hepatocellular carcinoma (Bai et al., 
2009; Coulouarn et al., 2009; Hsu et al., 2012; 
Kutay et al., 2006). In hepatocellular carcinoma cell 
lines, it is believed to inhibit proliferation by 
suppressing Wnt/β-catenin signaling (Xu et al., 
2012). miR-122 was determined to stabilize the 
tumour suppressor protein p53 by modulating 
Cyclin G1, with the added effect of enhancing 
hepatocellular carcinoma cells' susceptibility to 
treatment with doxorubicin (Fornari et al., 2009). 
Its expression is also inversely correlated with 
levels of the protein Pkm2, found in hepatocellular 
carcinomas (Jung et al., 2011). A subset of 
individuals with HCC bear a polymorphism 
(rs3783553) in the 3' UTR of IL-1α which is 
hypothesized to disrupt a miR-122 binding site. IL-
1α is implicated in carcinogenesis and tumour 
growth, as well as immune responses to tumours, 
and miR-122 regulation of IL-1α under normal 
circumstances may be an aspect of its tumour 
suppressor function (Gao et al., 2009). Loss of 
miR-122 expression led to increased cell migration 
and invasion, while restoration of miR-122 
suppressed these effects (Coulouarn et al., 2009). 
miR-122 gene knockout mice are prone to hepatic 
tumour development, while delivery of miR-122 to 
these mice strongly inhibited tumourigenesis (Hsu 
et al., 2012). 
In anaplastic thyroid cancer, miR-122 levels 
increase in thyroid cancer cell lines that respond to 
treatment with a PAX8/PPARγ fusion protein, both 
in vitro and in xenografts (Reddi et al., 2013). 
Lipid metabolism 
Note 
Microarrays have shown that miR-122 antagonism 
decreases the expression of several genes crucial to 
lipid metabolism, including ACC1, ACC2, ACLY, 
SCD1, and SREBP2, which contribute to fatty acid 
metabolism, and PMVK, which is essential for 
cholesterol biosynthesis (Esau et al., 2006). These 
mRNAs are not predicted to be direct targets of 
miR-122, so it is hypothesized that miR-122 may 
indirectly promote their expression by suppressing 
a transcriptional repressor (Esau et al., 2006). 
Consistent with these findings, miR-122 
antagonism decreases serum cholesterol levels in 
chimpanzees (Lanford et al., 2010). Recently, Hsu 
et al. (2012) used miR-122 knock-out mice to 
identify AGPAT1 and CIDEC as direct targets of 
miR-122. CIDEC, also called FSP27, is associated  
MIR122 (microRNA 122) Gailius J, et al. 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(7) 474 
with lipid droplets and regulates triglyceride storage 
and fatty acid oxidation at these sites (Keller et al., 
2008; Vilà-Brau et al., 2013). In the liver, CIDEC is 
induced during the initial stages of fasting, but 
decreases during late fasting (Vilà-Brau et al., 
2013). CIDEC is believed to be regulated by the 
PKA-CREB-CRTC2 pathway (Vilà-Brau et al., 
2013), and the role of miR-122 in CIDEC 
regulation remains to be determined.  
AGPAT1 is involved in regulating the energy state 
in adipose and muscle tissues (Takeuchi and Reue, 
2009). Overexpression studies show that AGPAT1 
stimulates the conversion of fatty acids into 
triglycerides (Ruan and Pownall, 2001). 
Translational repression, mediated by miR-122 and 
the RISC, reduces the expression of CIDEC and 
AGPAT1 in hepatocytes (Hsu et al., 2012), and this 
inhibits the storage of triglycerides in liver tissue. 
miR-122 also directly targets cationic amino acid 
transporter 1 (CAT-1) mRNA (Chang et al., 2004), 
a membrane transporter expressed predominantly in 
peripheral tissues.  
In summary, research has demonstrated that miR-
122 directly and indirectly regulates lipid 
metabolism in the liver, but the mechanism of 
indirect regulation is unknown. 
Liver damage 
Note 
Serum miR-122 has been identified as a potential 
biomarker for liver damage from many sources 
(Laterza et al., 2013). While some studies 
determine that serum miR-122 can be used to 
differentiate between different types of liver 
damage, especially when combined with other 
serum miRNAs, a comprehensive study has not yet 
been done to generate a diagnostic signature for the 
different causes of liver damage investigated. In 
both human and murine models of liver damage 
from alcohol and from Hepatitis B, miR-122 levels 
were elevated under damaged conditions, with 
levels correlating to disease scoring and severity 
(Zhang et al., 2010). In response to acute 
hepatotoxicity in humans, Ding et al. found miR-
122 levels correlated with serum ALT levels, and 
further noted that when comparing HBV-associated 
liver damage to HCC-associated liver damage, the 
miR-122 profiles were distinct (Ding et al., 2012). 
miR-122 levels correlated with disease severity - 
although not viral titer - in chronically HCV-
infected patients, and in patients with non-alcoholic 
fatty liver disease (Cermelli et al., 2011). In a rat 
model of liver transplantation, plasma miR-122 was 
evaluated as a marker of pending transplant 
rejection. In this instance, miR-122 expression was 
up-regulated upon liver damage (pre-
transplantation), but did not signal transplant 
rejection (Hu et al., 2013). However, in human liver  
transplants, not only was miR-122 identified as a 
biomarker for liver damage, its expression was also 
significantly increased prior to and during acute 
transplant rejection (Farid et al., 2012). Starkey 
Lewis et al. demonstrated increased serum levels of 
miR-122 in patients experiencing acute 
acetaminophen poisoning, and observed that miR-
122 levels were higher than with other forms of 
acute liver damage (Starkey Lewis et al., 2011). 
Finally, in a mouse model system, Bala et al. noted 
that the circulating form of miR-122, in 
combination with elevated or reduced levels, could 
be used to not only detect liver damage, but also to 
differentiate between causes: drug-induced injury 
led to miR-122 being found in the protein fraction 
of the mouse serum, while alcohol and 
inflammation-induced liver damage led to 
circulation of miR-122 in exosomes (Bala et al., 
2012). 
Liver development 
Note 
Hepatocyte nuclear factor 6 (HNF6), a hepatocyte-
specific transcription factor, promotes miR-122 
expression in hepatocytes (Laudadio et al., 2012). 
miR-122, in turn, enhances the expression of HNF6 
and other liver-enriched transcription factors 
(LETFs), establishing a positive-feedback loop 
(Laudadio et al., 2012).  
Along with other LETFs, HNF6 participates in a 
network of transcriptional regulation essential for 
the terminal differentiation of hepatocytes (Kyrmizi 
et al., 2006).  
miR-122 also downregulates CUTL1, a 
transcription factor that represses genes required for 
hepatocyte differentiation (Xu et al., 2010), thus 
promoting hepatocyte differentiation. 
Circadian rhythm 
Note 
Circadian expression of the miR-122 locus is under 
the control of two retinoid-related orphan receptor 
elements (ROREs) (Gatfield et al., 2009), on which 
REV-ERBα acts (Ueda et al., 2002).  
REV-ERBα is a transcription factor that plays key 
roles in the regulation of circadian transcriptional 
feedback loops (Reppert and Weaver, 2002). In the 
mouse liver, mature miR-122 levels remain 
relatively constant, but pre- and pri-miR-122 levels 
fluctuate over the course of the circadian cycle 
(Gatfield et al., 2009).  
The levels of these intermediates are lowest at 
Zeitgeber Time (ZT) 8-12 and highest at ZT24, and 
these periods correspond to the peak and minimal 
expression of REV-ERBα (Gatfield et al., 2009). 
Many miR-122 targets also demonstrate circadian 
fluctuations in expression that are concomitant with 
miR-122 fluctuation (Gatfield et al., 2009). 
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Figure 4. Two molecules of miR-122 (blue) binding to the 5' UTR of the HCV RNA (black) with the seed sequence in bold. 
Binding outside of the seed sequence is shown by un-bolded pairing of miR-122 and viral RNA (Thibault et al., 2013). 
 
Iron homeostasis 
Note 
miR-122 directly targets the hemochromatosis 
(Hfe) and hemojuvelin (Hjv) mRNAs for 
suppression (Castoldi et al., 2011). Hfe and Hjv 
activate hepcidin, a hormone that controls systemic 
iron levels (Nemeth et al., 2004). Hepcidin binds to 
and induces the degradation of ferroportin, an iron 
efflux channel expressed on cells able to release 
iron, including macrophages and hepatocytes 
(Castoldi and Muckenthaler, 2012). By suppressing 
the activators of hepcidin, miR-122 prevents 
hepcidin from interacting with ferroportin (Castoldi 
et al., 2011). This model is supported by the 
observation that miR-122 depletion leads to iron 
deficiency (Castoldi et al., 2011). 
Hepatitis C virus (HCV) infection 
Note 
HCV RNA bears two miR-122 binding sites in its 5' 
UTR (Jopling et al., 2008; Jopling et al., 2005). 
miR-122 binding has been shown to be critical to 
the viral life cycle by enhancing viral stability and 
translation, as well as other possible mechanisms 
that have yet to be determined, and has been 
proposed as the factor that defines the virus' liver 
tropism (Henke et al., 2008; Sedano, 2012; 
Shimakami et al., 2012). This interaction requires 
the miRNA RISC protein Argonaute-2, but is 
otherwise non-canonical, as the miRNA binds both 
with its seed sequence and with other sequences to 
the 3' end of the miRNA (Machlin et al., 2011; 
Wilson et al., 2011). Along with the role it plays in 
the virus life cycle, miR-122 has been identified as 
a potential serum marker for HCV-induced liver 
damage and hepatocellular carcinoma (Bihrer et al., 
2011; Cermelli et al., 2011; Ding et al., 2012; van 
der Meer et al., 2013). 
Disease 
Hepatitis C Virus is a blood-borne infection that 
frequently progresses to chronicity, and can lead to 
liver-associated diseases such as metabolic 
syndrome, steatosis, cirrhosis, decompensated liver 
disease and liver failure, and hepatocellular 
carcinoma. It can also have extra-hepatic 
manifestations such as cryoglobulinemia and other 
auto-immune disorders, or neurological symptoms 
such as depression and cognitive impairment 
(Maasoumy and Wedemeyer, 2012). 
Prognosis 
HCV infection can be cured in a growing number 
of patients, as new direct-acting antiviral therapies 
are developed. Current treatment involves a lengthy 
course of pegylated interferon-alpha injections and 
ribavirin; for patients infected with HCV genotype 
1, the protease inhibitors Telaprevir or Boceprevir 
are included in the treatment. Host genetics and 
health status, along with viral genotype, strongly 
influence the potential effectiveness of treatment. 
Without treatment, infection can progress to the 
diseases above (Myers et al., 2012; Ramachandran 
et al., 2012). 
Oncogenesis 
A proportion of patients with a chronic hepatitis C 
virus infection progress to hepatocellular 
carcinoma, although the mechanisms of 
oncogenesis are not yet firmly identified. The virus' 
proteins have been implicated in manipulating host 
cell signaling by downregulating, upregulating, or 
sequestering host factors (including the tumour-
suppressor miR-122), leading to oncogenesis. 
Finally, as HCV is a chronic infection, the 
immunopathology from long-term low-grade 
inflammation can cause fibrosis, promoting 
cirrhosis and eventually carcinogenesis (Bühler and 
Bartenschlager, 2012). 
Hepatitis B virus (HBV) infection 
Note 
Loss of miR-122 in hepatitis B virus infection leads 
to increased viral replication; miR-122 was shown 
to suppress Cyclin G1 expression, which in turn 
releases the antiviral and anti-tumour protein p53 
(Wang et al., 2012b). Conversely, addition of miR-
122 was shown to inhibit HBV replication, and was 
proposed to limit HBV-associated hepatocellular 
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carcinoma by suppressing NDRG3 (Fan et al., 
2011). miR-122 has also been shown to directly 
bind to conserved HBV sequences, suppressing 
viral replication; in apparent response to this, the 
HBx viral protein inhibits miR-122 expression by 
binding PPARγ, a transcriptional activator of miR-
122 (Chen et al., 2011; Song et al., 2013). 
In addition, HBV has been observed to overproduce 
the targeted transcript to act as a miR-122 sponge 
(Li et al., 2013). miR-122 has been proposed as a 
serum marker for HBV-associated liver damage and 
hepatocellular carcinoma, as a means of detecting 
active and occult HBV infections, and of predicting 
patient risk of HBV disease progression (Chen et 
al., 2012; Ding et al., 2012; Qi et al., 2011; 
Waidmann et al., 2012; Zhang et al., 2010). 
Disease 
Hepatitis B virus infection is a blood-borne 
infection that progresses to chronicity in about 5% 
of adult acute infections, although the risk is much 
higher in children and infants (Kuo and Gish, 
2012). The most common and most severe 
complications from HBV infection are liver 
cirrhosis, hepatic decompensation, and 
hepatocellular carcinoma, although extrahepatic 
manifestations associated with immune complex-
mediated injury are also fairly frequent (Liang, 
2009; Nebbia et al., 2012).  
HBV-infected patients are also at risk from co-
infection with a dependovirus, hepatitis D virus, 
which can only replicate in the presence of HBV, as 
it uses HBV proteins in its own infection cycle. 
HDV can exacerbate symptoms and progression of 
HBV infection (Farci and Niro, 2012). 
Prognosis 
HBV infections cannot be cured, but a functional 
cure can be effected in many patients through 
treatment with pegylated interferon and/or 
nucleo(t/s)ide analogues to suppress viral 
replication and eliminate circulating virus and 
antigens.  
Suppressing the virus in patients with an active 
infection reduces the risk of developing HBV-
associated pathologies, including hepatocellular 
carcinoma (Kuo and Gish, 2012; Liaw, 2013). 
However, because the viral DNA is still present, 
since it integrates into the host genome, 
functionally cured patients experiencing 
immunosuppression are at risk of virus reactivation 
(Nebbia et al., 2012). 
Oncogenesis 
HBV does not have direct cytopathology associated 
with infection, and oncogenesis is instead attributed 
to chronic inflammation of the liver - causing 
fibrosis, cirrhosis, and eventually hepatocellular 
carcinoma - and the ability of the viral DNA to 
integrate randomly in the host chromosomes, 
resulting in loss of cellular regulation. The viral  
protein HBx manipulates cell cycle progression and 
host cell transcription patterns (including 
transcription of miR-122), and truncated mutants 
have been implicated in tumour production. Certain 
HBV mutants and HBV genotype C are also 
associated with higher risk of oncogenesis (Fallot et 
al., 2012). 
Up-regulated by alcohol 
consumption 
Note 
Alcohol consumption appears to up-regulate miR-
122 expression, which in turn suppresses 
expression of Cyclin G1 (Hou et al., 2013).  
This may be mediated by production of HSP90, and 
its interaction with the protein GW182, which is 
involved in the microRNA silencing pathway 
(Bukong et al., 2013).  
In a rat model, miR-122 levels in the liver were 
significantly increased after chronic alcohol 
exposure (three weeks) (Dippold et al., 2013). This 
is believed to have a positive effect on hepatitis C 
Virus replication (Bukong et al., 2013; Hou et al., 
2013). 
Non-alcoholic fatty liver disease 
(NAFLD) and steatohepatitis (NASH) 
Note 
miR-122 was downregulated in rats fed different 
diets that induce non-alcoholic fatty liver disease 
(Alisi et al., 2011). Mice fed with a high fat 
(NAFLD-inducing) diet, then treated with a miR-
122 antagonist, demonstrated lowered serum 
cholesterol and some lipogenic genes were 
downregulated (Esau et al., 2006).  
Liver biopsies of patients with non-alcoholic 
steatohepatitis, on the severe end of the NAFLD 
spectrum, identified significantly lowered levels of 
miR-122 in these patients, in comparison to healthy 
control patients; this is suggested to dysregulate 
lipid metabolism and exacerbate the disease 
(Cheung et al., 2008).  
However, increased serum levels of miR-122 
positively correlated with disease severity in 
NAFLD patients, although this may not be 
mechanistically associated with the disease 
(Cermelli et al., 2011). 
Hyperlipidaemia and coronary artery 
disease 
Note 
Blood plasma levels of miR-122 were elevated in 
patients with hyperlipidaemia; levels of miR-122 
positively correlated with severity of coronary 
artery disease in patients, and also correlated with 
increased serum levels of total cholesterol, 
triglycerides, and low-density lipoprotein 
cholesterol in both control and diseased patients 
(Gao et al., 2012). 
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Cardiac arrest 
Note 
miR-122 has been identified as a potential 
biomarker for neurological outcome after cardiac 
arrest. In a porcine model of cardiac arrest, high 
levels of plasma miR-122 were detected after 
induction of cardiac arrest (Andersson et al., 2012). 
Although miR-122 was not correlated with 
inflammation or cardiac damage, in a human study, 
increased serum levels of miR-122 were found in 
patients with poor neurological outcome (miR-122 
is expressed at low levels in neurons) and were 
associated with elevated mortality (Stammet et al., 
2012). 
Sepsis 
Note 
Reduced serum levels of miR-122 were identified 
in patients with sepsis, as compared to non-septic 
patients. However, the degree of reduction did not 
correlate with severity of sepsis (Wang et al., 
2012a). 
Borna disease virus (BDV) 
Note 
Borna disease virus is a neurotropic virus that has 
been identified to contain miR-122 binding sites. 
Functional assays determined that miR-122 exerts a 
direct suppressive effect on viral replication and 
translation; it also appears to indirectly impact viral 
replication by enhancing interferon signaling (Qian 
et al., 2010). 
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